Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Belantamab Mafodotin→

Belantamab Mafodotin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2050232-20-5
Molecular formula
Not available
Molecular weight
Not available
Drug class
BCMA-directed antibody–drug conjugate (ADC)antineoplastic biologic
Mechanism of action
The antibody binds B-cell maturation antigen (BCMA) on myeloma cells and is internalised. Intracellular release of the microtubule-disrupting payload monomethyl auristatin F (MMAF) inhibits tubulin polymerisation, causes cell-cycle arrest and induces apoptosis; antibody-dependent cellular cytotoxicity may also contribute.
Indications / reported uses
  • In combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, under the US FDA approval of 23 Oct 2025

Sources: US FDA — Belantamab mafodotin approval (23 Oct 2025) · FDA approval letter — Blenrep · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Belantamab Mafodotin Environmental Risk Assessment (ERA) (the Belantamab Mafodotin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.